News and Announcements
OpenDNA Launches New Tool from AI System
- Published October 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- OpenDNA Ltd (ASX: OPN) has launched it’s newest product, Synapse, utilising its AI systems.
- The tool will allow customers with a deeper insight into the interests and psychographics of their users.
- This will provide OpenDNA customers business-ready tools and actionable data.
Highly experienced developer and fund manager, OpenDNA Ltd (ASX: OPN) has launched it’s newest tool, Synapse, a suite of business tools to allow customers a thorough understanding of their users’ interests and psychographics.
Consumers utilizing Synapse can more effectively hit, retain, and convert users of their services. Depending on the business team concentrating on acquiring new users, upselling existing buyers, or effortlessly deepening engagement of content consumers, Synapse renders concise tools to elevate their specific metrics.
OpenDNA’s CEO and MD had informed the ASX that “the release of Synapse enables the power of the OpenDNA AIS platform to grow exponentially, by giving our customers new and robust ways of looking and acting on the data and insights that the platform provides. We are continually exploring ways to leverage our AI technology and to deliver relevant, practical outcomes for customers which improve the already-compelling business proposition that our personalisation technology provides. We understand our customers’ requirements for business-ready tools and actionable data – not just data for data’s sake – and Synapse comprehensively addresses those requirements.”
About OpenDNA Ltd (ASX: OPN)
To businesses, OpenDNA provides real-time insights into their individual customers’ behaviour which allows them to better predict their needs. This enables businesses to deliver a more relevant customer experience at an individual level, which drives increased revenue. OpenDNA’s artificial intelligence and machine-learning system automatically creates detailed psychographic user profiles, which helps deliver better business outcomes.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
